Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: A preliminary report

International Journal of Clinical Oncology

Volumn 8, Issue 1, 2003, Pages 49-52

  Shimoyama, Shouji ^a   Aoki, Fumio ^a   Shimizu, Nobuyuki ^a   Tatsutomi, Yusuke ^a   Mafune, Ken ichi ^a   Kaminishi, Michio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Advanced gastric cancer; Cisplatin; CPT 11; Quality of life

Indexed keywords

ANTIEMETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; DEXAMETHASONE; FUROSEMIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; SCOPOLAMINE BUTYL BROMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY INJURY; LIVER TOXICITY; MALE; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CARCINOMA; TREATMENT OUTCOME;

AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037297690     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470300007     Document Type: Article

References (19)

1. Hsiang Y-H, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanisms of cell killing by camptothecin. Cancer Res 49:5077-5082
2. Saltz L, Shimada Y, Khayat D (1996) CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 32A(Suppl 3):S24-S31
3. Masuda N, Fukuoka M, Takada M, et al. (1992): CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780
4. Shimoyama S, Aoki F, Murakami T, et al. (2000) The feasibility of daily concurrent chemoradiation therapy as a nonsurgical management for esophageal cancer: our experience and theoretical backgrounds. J Surg Oncol 74:134-137
5. Kano Y, Suzuki K, Akutsu M, et al. (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610
6. Masumoto N, Nakano S, Esaki T, et al. (1995) Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75
7. Futatsuki K, Wakui A, Nakao I, et al. (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer (in Japanese). Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 21:1033-1038
8. Sato A, Kurihara M, Matsukawa M, et al. (2001) Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 47:380-384
9. Boku N, Ohtsu A, Shimamda Y, et al. (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
10. Ajani JA, Baker J, Pisters PW, et al. (2001) Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology 15:52-54
11. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer 1:10-24
12. Oken MM, Creech RH, Tormey DC, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
13. Trotti A, Byhardt R, Stetz J, et al. (2000) Common toxicity criteria version 2.0: an improved reference for grading the acute effects of cancer treatment. Impact on radiology. Int J Radiat Oncol Phys 47:13-47
14. Kudoh S, Fukuoka M, Masuda N, et al. (1995) Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 86:406-413
15. de Forni M, Bugat R, Chabot GG, et al. (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354
16. Abigerges D, Chabot GG, Armand JP, et al. (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221
17. Armand JP (1996) CPT-11: clinical experience in phase I studies. Semin Oncol 23:27-33
18. Sato A, Yamamoto W, Takebuchi K, et al. (2001) Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer (in Japanese). Nippon Rinsho (Jpn J Clin Med) 59:616-620
19. Houghton PJ, Cheshire PJ, Hallman JC. et al. (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829